Sunday, February 28, 2016

6:00 p.m.-7:00 p.m.  Opening Keynote Session  
Plaza D-F  
**Session Chair: Karen E. Knudsen,**  
Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA

6:00 p.m.-6:05 p.m.  Welcome

6:05 p.m.-7:00 p.m.  Keynote Address: New Insights into Quiescence Control  
**David M. Livingston,** Dana-Farber Cancer Institute, Boston, MA

7:00 p.m.-9:00 p.m.  Opening Reception  
Plaza G-H

Monday, February 29, 2016

7:30 a.m.-8:30 a.m.  Breakfast and Roundtable Discussions  
Plaza G-H

8:30 a.m.-10:30 a.m.  Plenary Session 1 G1 Advances: Novel Insights into G1 CDK/cyclins  
Plaza D-F  
**Session Chair: Manuel Serrano,**  
Spanish National Cancer Center (CNIO), Madrid, Spain

8:30 a.m.-9:00 a.m.  Neomorphic functions of cyclin D1 during neoplastic development  
**J. Alan Diehl,** Medical University of South Carolina, Charleston, SC

9:00 a.m.-9:30 a.m.  Identification of cell cycle-regulating microRNAs  
**Peter Sicinski,** Dana-Farber Cancer Institute, Boston, MA

9:30 a.m.-10:00 a.m.  The Targeting of CDK4/6: Have we gone full circle?  
**Gary K. Schwartz,** Columbia University Irving Comprehensive Cancer Center, New York, NY

10:00 a.m.-10:15 a.m.  Therapeutic targeting of cdk4 in bladder cancer  
**Jesus Paramio,** Biomedical Research Institute University Hospital, Madrid, Spain

10:15 a.m.-10:30 a.m.  Targeting the Brk:p27:cdk4 axis in Breast Cancer  
**Stacy Blain,** SUNY Downstate Medical Center, Brooklyn, NY

10:30 a.m.-11:00 a.m.  Break  
Plaza D-F Lobby
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chair/Presenter</th>
<th>Details</th>
</tr>
</thead>
</table>
| 11:00 a.m.-1:00 p.m. | Plenary Session 2 Targeting CDK/cyclins: Hormone Dependent Cancers and Beyond              | Plaza D-F               | Helen Piwnica-Worms, UT MD Anderson Cancer Center, Houston, TX | Title to be announced  
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA  
Co-targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer  
Maha H. Hussain, University of Michigan Medical School, Ann Arbor, MI  
Targeting the cyclin D-CDK4/6 pathway for cancer therapy  
Robert T. Abraham, Pfizer Pharmaceuticals, San Diego, CA (Not eligible for CME credit)  
Reprogramming human cancer cells in CDK4/6 inhibitor therapy  
Selina Chen-Kiang, Weill Cornell Medical College of Cornell University, New York, NY |
| 1:00 p.m.-3:30 p.m.  | Poster Session A and Lunch                                                                 | Plaza G-H               |                                                      |                                                                                                                                      |
| 3:30 p.m.-5:30 p.m.  | Plenary Session 3 Getting out of Cycle: G0 and Senescence                                  | Plaza D-F               | Charles J. Sherr, St. Jude Children's Research Hospital, Memphis, TN | A drug delivery method selective for senescent cells  
Manuel Serrano, Spanish National Cancer Center (CNIO), Madrid, Spain  
The senescence response – yin and yang  
Judith Campisi, Buck Institute for Research on Aging, Novato, CA  
Transient CDK4/6 inhibition protects hematopoietic progenitors from chemotherapy-induced exhaustion  
Norman E. Sharpless, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC  
Extended inhibition of CDK4/6 inhibits mTORC1 signaling and induces therapeutic senescence in vemurafenib resistant melanoma  
Akihiro Yoshida, Medical University of South Carolina, Charleston, SC  
Characterizing the sequence of cell-cycle events during proliferation and quiescence  
Sabrina Spencer, University of Colorado-Boulder, Boulder, CO |
| Tuesday, March 1, 2016 |                                                                                           |                         |                                                      |                                                                                                                                      |
| 7:30 a.m.-8:30 a.m.  | Breakfast and Roundtable Discussions                                                      | Plaza G-H               |                                                      |                                                                                                                                      |
| 8:30 a.m.-10:30 a.m. | Plenary Session 4 Rb Bench to Bedside: Novel Functions and Clinical Implications          | Plaza D-F               | Jacqueline A. Lees, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA |

CANCER CELL CYCLE: TUMOR PROGRESSION AND THERAPEUTIC RESPONSE
8:30 a.m.-9:00 a.m. Targeting the cell cycle in pediatric solid tumors
   Michael A. Dyer, St. Jude Children’s Research Hospital, Memphis, TN

9:00 a.m.-9:30 a.m. Modeling RB mutant human cancers in mice to identify novel therapeutic targets
   Julien Sage, Stanford University School of Medicine, Stanford, CA

9:30 a.m.-10:00 a.m. Interplay of the RB axis with hormone signaling: Mechanisms and novel therapeutic strategies
   Karen E. Knudsen, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA

10:00 a.m.-10:15 a.m. RB localizes to DNA double strand breaks and promotes DNA end resection and homologous recombination through the recruitment of SWI/SNF complex
   Renier Velez-Cruz, The University of Texas MD Anderson Cancer Center, Smithville, TX

10:15 a.m.-10:30 a.m. Sox2 functions as a critical tumor suppressor in Rb loss initiated tumors
   Michael Kareta, Stanford University, Stanford, CA

10:30 a.m.-11:00 a.m. Break
   Plaza D-F Lobby

11:00 a.m.-1:00 p.m. Plenary Session 5 E2F Family Functions: Alterations and Consequences
   Plaza D-F
   Session Chair: Peter Sicinski, Dana-Farber Cancer Institute, Boston, MA

11:00 a.m.-11:30 a.m. The consequences of pRb inactivation: insights from a proteomic analysis of Rb loss
   Nicholas Dyson, Massachusetts General Hospital Cancer Center, Charlestown, MA

11:30 a.m.-12:00 p.m. Breaking the balance between E2F Activators and Atypical Repressors: Consequences to Development and Cancer
   Gustavo W. Leone, Ohio State University Comprehensive Cancer Center, Columbus, OH

12:00 p.m.-12:30 p.m. Title to be announced
   Jacqueline A. Lees, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

12:30 p.m.-12:45 p.m. Recruitment of Pontin/Reptin by E2F1 amplifies E2F transcriptional response during cancer progression
   Patrick Viatour, Children’s Hospital of Philadelphia, Philadelphia, PA

12:45 p.m.-1:00 p.m. RB loss elicits extensive re-programming of AR and E2F1 in prostate cancer
   Christopher McNair, Thomas Jefferson University, Philadelphia, PA

1:00 p.m.-3:00 p.m. Lunch (on own)
3:00 p.m.-5:00 p.m.  Plenary Session 6 Replication Stress and DNA Damage Response
Plaza D-F

Session Chair: Caroline Dive,
CRUK Manchester Institute, Manchester, UK

3:00 p.m.-3:30 p.m.  Functional analysis of mammalian Polθ reveals its role in double-strand break repair
Agnel J. Sfeir, New York University Langone Medical Center, New York, NY

3:30 p.m.-4:00 p.m.  Mechanisms of alternative telomere recombination
Roger A. Greenberg, University of Pennsylvania, Philadelphia, PA

4:00 p.m.-4:30 p.m.  Exploiting CDK2-driven replication stress to repurpose cancer chemotherapy
Bruce Clurman, Fred Hutchinson Cancer Research Center, Seattle, WA

4:30 p.m.-4:45 p.m.  c-MYC preserves genomic integrity during DNA replication: a paradigm shift of c-MYC
Alpana Kumari, Augusta University, Augusta, GA

4:45 p.m.-5:00 p.m.  Exploiting the G2-M cell cycle checkpoint dependency in small cell lung cancer (SCLC) using pharmacological inhibitors of CHK1 and WEE1
Triparna Sen, UT MD Anderson Cancer Center, Houston, TX

5:00 p.m.-5:15 p.m.  Break
Plaza D-F Lobby

5:15 p.m.-6:15 p.m.  Keynote Address
Plaza D-F

Session Chair: J. Alan Diehl,
Medical University of South Carolina, Charleston, SC

Mitogenic Signaling and the RB/p53 Network
Charles J. Sherr, St. Jude Children’s Research Hospital, Memphis, TN

6:15 p.m.-8:30 p.m.  Poster Session B and Reception
Plaza G-H

Wednesday, March 2, 2016

7:30 a.m.-8:30 a.m.  Breakfast and Roundtable Discussions
Plaza G
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m.-10:45 a.m.</td>
<td>Plenary Session 7 Managing G2/M Control</td>
<td>Plaza D-F</td>
</tr>
<tr>
<td></td>
<td><strong>Session Chair: J. Alan Diehl,</strong> Medical University of South Carolina, Charleston, SC</td>
<td></td>
</tr>
<tr>
<td>8:30 a.m.-9:00 a.m.</td>
<td>Circulating tumour cell derived explant models to study the effects of cell cycle targeted drugs in small cell lung cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Caroline Dive,</strong> CRUK Manchester Institute, Manchester, UK</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.-9:30 a.m.</td>
<td>Cyclin A2 controls genome stability through CDK-dependent and independent mechanisms</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Jan M. Van Deursen,</strong> Mayo Clinic, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>9:30 a.m.-10:00 a.m.</td>
<td>Checkpoint signaling and targeting in cancer cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Helen Piwnica-Worms,</strong> UT MD Anderson Cancer Center, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>10:00 a.m.-10:15 a.m.</td>
<td>APC/CCdh1 maintains primordial follicles, germinal vesicle arrest and ensures balanced segregation of chromosomes by enabling removal of Shugoshin-2 from chromosomes arms</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ahmed Rattani,</strong> Mount Auburn Hospital, Harvard Medical School, Cambridge, MA</td>
<td></td>
</tr>
<tr>
<td>10:15 a.m.-10:30 a.m.</td>
<td>Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in patient-derived Glioblastoma stem-like cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Patrick Paddison,</strong> Fred Hutchinson Cancer Research Center, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.-10:45 a.m.</td>
<td>Germ-line mutations in CDC20 result in familial cancers via deregulation of the cell cycle</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ester Castellsague,</strong> McGill University, Montreal, Canada</td>
<td></td>
</tr>
<tr>
<td>10:45 a.m.-11:15 a.m.</td>
<td>Break</td>
<td>Plaza D-F Lobby</td>
</tr>
<tr>
<td>11:15 a.m.-1:00 p.m.</td>
<td>Plenary Session 8 Derailed by Infection: Viral-mediated Cell Cycle Dysfunction</td>
<td>Plaza D-F</td>
</tr>
<tr>
<td></td>
<td><strong>Session Chair: Julien Sage,</strong> Stanford University School of Medicine, Stanford, CA</td>
<td></td>
</tr>
<tr>
<td>11:15 a.m.-11:45 a.m.</td>
<td>Merkel cell polyomavirus Small T antigen recruits MYCL to the TRRAP-p400 complex to promote oncogenesis and re-programming</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>James A. DeCaprio,</strong> Dana-Farber Cancer Institute, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>11:45 a.m.-12:15 p.m.</td>
<td>Title to be announced</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maura Gillison,</strong> Ohio State University Comprehensive Cancer Center, Columbus, OH</td>
<td></td>
</tr>
<tr>
<td>12:15 p.m.-12:45 p.m.</td>
<td>Perturbation of host cellular regulatory networks by human papillomaviruses</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Karl Munger,</strong> Tufts University School of Medicine, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>12:45 p.m.-1:00 p.m.</td>
<td>Real-time in vivo image-guided cell-cycle perturbation to increase tumor chemosensitivity</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Shuya Yano,</strong> Okayama University, Okayama, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Not eligible for CME credit)</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.-1:15 p.m.</td>
<td>Closing Remarks and Departure</td>
<td>Plaza D-F</td>
</tr>
</tbody>
</table>